CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
50 mg PTI-125 +2 moredrug
Likely dose
50 mg PTI-125from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03784300
NCT03784300Phase 1Completed
CompareCT.gov

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Pain Therapeutics·interventional·Posted Dec 21, 2018·Updated May 10, 2021

In Brief

A Phase 1 clinical trial evaluating 50 mg PTI-125, 100 mg PTI-125, and 1 other intervention for Alzheimer Disease, Early Onset and Alzheimer Disease. Completed, enrolled 24 participants across 1 site.

Detailed Summary

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Early Onset, Alzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedDec 21, 2018
Enrollment StartAug 18, 2017
Primary CompletionOct 9, 2017
Study CompletionMar 27, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.5 years ago

Interventions

50 mg PTI-125drug

PTI-125 50 mg Oral Solution

100 mg PTI-125drug

PTI-125 100 mg Oral Solution

200 mg PTI-125drug

PTI-125 200 mg Oral Solution